Select Transactions

Avenue Therapeutics
Sale of stock and conditional sale to
$215 million + CVRs
February 2019
Debt recapitalization and acquisition of NextWave Pharmaceuticals from
$125 million
September 2018
Rubicon Research
Majority recap by
General Atlantic Partners
$125 million
April 2019
Acquisition of
generics business of
$1.05 billion
June 2017
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

Creating Value Through Intelligent Borrowing

Opportunities in the Life Sciences Debt Market

Torreya’s report provides an overview of the evolving landscape of the Life Sciences debt market. Key points include:

Click Here for Report Executive Summary   |    Click Here for Full Report